August 6, 2020
Via EDGAR Transmission
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: | BiondVax Pharmaceuticals Ltd. | |
Registration Statement on Form F-3 | ||
Filed July 29, 2020 | ||
Registration No. 333-240189 |
Ladies and Gentlemen:
In accordance with Rule 461 of the Rules and Regulations under the Securities Act of 1933, as amended, we hereby request the acceleration of the effective date of the above-referenced Registration Statement so that it will become effective on August 10, 2020 at 4:00 p.m. Eastern Time or as soon thereafter as practicable. Please contact our counsel, Gross, Kleinhendler, Hodak, Halevy, Greenberg, Shenhav & Co., attention: Perry Wildes at +972-3-607-4475, or in his absence, Joshua Ravitz at +972-3-607-4480, to provide notice of effectiveness, or if you have any other questions or concerns regarding this matter.
Very truly yours, | ||
BiondVax Pharmaceuticals Ltd. | ||
By: | /s/ Uri Ben Or | |
Uri Ben Or Chief Financial Officer |
Jerusalem BioPark, 2nd floor ● Hadassah Ein Kerem Campus ● Jerusalem, Israel
Telephone: +972-8-9302529 ● Fax: +972-8-9302531 ● www.BiondVax.com